Vision Gains From Aflibercept for Diabetic Macular Edema Persist for 5 Years

Source: Medscape

As-needed aflibercept treatment maintains vision gains in patients with diabetic macular edema (DME) through 5 years of treatment, even with reduced aflibercept dosing in the later years, according to results from the ENDURANCE extension study, according to a report in Medscape.

"Through the fourth and fifth years of DME management, a clinically meaningful proportion of patients, 25%, did not require any additional anti-VEGF (vascular endothelial growth factor) dosing to maintain the visual and anatomic gains achieved with prior regular anti-VEGF dosing,” Dr. Charles C. Wykoff from Retina Consultants of Houston and Blanton Eye Institute, Weill Cornell Medical College, also in Houston, told Reuters Health by email. “The majority, however, or 75% of patients, did receive at least one retreatment during the fourth and fifth years of treatment, with a mean of nearly 8 injections through 2 years.”

Read the full article here.

Related Content